VSV-GP-EpCAM-TcE / Boehringer Ingelheim - LARVOL DELTA

TcE armed oncolytic virus VSV-GP combines oncolysis and T-cell retargeting for improved efficacy (AACR 2024) - "Virus fitness was maintained for VSV-GP encoding the TcE molecule. Using co-culture assays, we demonstrated that EpCAM-TcE molecule is successfully expressed by VSV-GP and can activate both CD4+ and CD8+ T cells resulting in proliferation, degranulation, and cytokine secretion. Furthermore, we validated the concept using patient-derived HNSCC tumor slices which are representative of complex human tumor ecosystems."

Clinical • Oncolytic virus • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD34 • CD8 • IFNG • TNFA